Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
RESEARCH TOOLSreports
Coya Therapeutics, Inc. (COYA) Stock Price & Analysis
31 Followers
COYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.21 - $10.69
Previous Close$8.6
Volume25.22K
Average Volume (3M)97.90K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$32.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-10.2
Beta0.55
Next Earnings
May 08, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding14,542,579
10 Day Avg. Volume59,342
30 Day Avg. Volume97,899
Standard Deviation0.20
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$14.50Price Target Upside68.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Coya Therapeutics, Inc. News
PremiumCompany Announcements
Coya Therapeutics Financial Update and Performance Review
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCoya Therapeutics announced completion of enrollment in an investigator led phase II trial evaluating the use of low dose IL-2 in patients with mild-to-moderate Alzheimer's Disease, showing the company's progress in its clinical development pipeline.
Financial StabilityCOYA Therapeutics has significantly increased its cash position, enhancing its financial stability and ability to fund operations into the future.
Regulatory EnvironmentThe FDA's positive response to the role of biomarkers in neurology indicates a regulatory environment that may be favorable to Coya's approach.
Bears Say
BiotechnologyMDA, a marker of oxidative stress, was elevated in subjects but was not correlated with disease progression, suggesting limitations in its use as a biomarker.
Drug DevelopmentRecent trial failures in ALS treatments highlight the complexity of the disease and the need for novel approaches.
Healthcare & PharmaceuticalsThe failure of Relyvrio in ALS represents a significant setback in understanding and treating this aggressive disease.
---
Ownership Overview
6.99% Insiders
1.31% Mutual Funds
5.85% Other Institutional Investors
85.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.21 and its highest was $10.69 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is May 08, 2024 which is in 10 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Mar 19, 2024. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.257 by -$0.117.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -$0.3.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 14,542,579 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of $0.14 in its last earnings report, missing expectations of $0.257. Following the earnings report the stock price went up 2.13%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Among the largest hedge funds holding Coya Therapeutics, Inc.’s share is Greenlight Capital Inc. It holds Coya Therapeutics, Inc.’s shares valued at 9M.
---
Coya Therapeutics, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.50 (68.60% Upside)
$14.50 (68.60% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 806.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 21.5%
Last 30 Days ▲ 21.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.74%
12-Months-Change
Fundamentals
Return on Equity
-58.62%
Trailing 12-Months
Asset Growth
391.61%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
---
COYA Stock 12 Months Forecast
Average Price Target
$14.50
▲(68.60% Upside)
Technical Analysis
Best Analysts Covering COYA
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+74.06%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +74.06% per trade.
---